CA3049967C - ANTI-IgE ANTIBODIES: THERAPIES AND ASSOCIATED METHODS AND COMPOSITIONS - Google Patents

ANTI-IgE ANTIBODIES: THERAPIES AND ASSOCIATED METHODS AND COMPOSITIONS

Info

Publication number
CA3049967C
CA3049967C CA3049967A CA3049967A CA3049967C CA 3049967 C CA3049967 C CA 3049967C CA 3049967 A CA3049967 A CA 3049967A CA 3049967 A CA3049967 A CA 3049967A CA 3049967 C CA3049967 C CA 3049967C
Authority
CA
Canada
Prior art keywords
seq
antibodies
subject
ige
hlaaiges
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3049967A
Other languages
English (en)
French (fr)
Other versions
CA3049967A1 (en
Inventor
Andrew Saxon
Ke Zhang
Original Assignee
Sixal Inc
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62789396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3049967(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sixal Inc, University of California San Diego UCSD filed Critical Sixal Inc
Publication of CA3049967A1 publication Critical patent/CA3049967A1/en
Application granted granted Critical
Publication of CA3049967C publication Critical patent/CA3049967C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3049967A 2017-01-06 2018-01-05 ANTI-IgE ANTIBODIES: THERAPIES AND ASSOCIATED METHODS AND COMPOSITIONS Active CA3049967C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443547P 2017-01-06 2017-01-06
US62/443,547 2017-01-06
PCT/US2018/012479 WO2018129248A1 (en) 2017-01-06 2018-01-05 Therapeutic anti-ige antibodies and methods and compositions thereof

Publications (2)

Publication Number Publication Date
CA3049967A1 CA3049967A1 (en) 2018-07-12
CA3049967C true CA3049967C (en) 2024-10-01

Family

ID=62789396

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3049967A Active CA3049967C (en) 2017-01-06 2018-01-05 ANTI-IgE ANTIBODIES: THERAPIES AND ASSOCIATED METHODS AND COMPOSITIONS

Country Status (6)

Country Link
US (2) US11518818B2 (cg-RX-API-DMAC7.html)
EP (1) EP3565587A4 (cg-RX-API-DMAC7.html)
JP (2) JP7128191B2 (cg-RX-API-DMAC7.html)
AU (1) AU2018205484B2 (cg-RX-API-DMAC7.html)
CA (1) CA3049967C (cg-RX-API-DMAC7.html)
WO (1) WO2018129248A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154627A1 (en) * 2019-01-25 2020-07-30 Promab Biotechnologies, Inc. Epcam antibody and epcam-car-t cells

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2296839T3 (es) * 1991-08-14 2008-05-01 Genentech Inc. Variantes de inmunoglobulinas para receptores fc-epsilon especificos.
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
HK1048127A1 (en) 2000-01-14 2003-03-21 Daiichi Pharmaceutical Co., Ltd. Novel peptide and screening method by using the same
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
CA2514840C (en) 2003-02-01 2017-11-07 Tanox, Inc. High affinity, anti-human ige antibodies
KR101581659B1 (ko) 2004-02-02 2015-12-31 타녹스 인코퍼레이티드 신규한 ＩｇＥ 에피토프의 확인
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
WO2008070593A2 (en) * 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
CA2682927A1 (en) * 2007-04-02 2008-10-16 Amgen Fremont Inc. Anti-ige antibodies
US8043620B2 (en) * 2007-11-21 2011-10-25 Amgen Inc. Wise binding agents and epitopes
CA2818621A1 (en) * 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
TW201334789A (zh) * 2012-01-31 2013-09-01 Genentech Inc 抗ｉｇｅ抗體及其使用方法
US10377827B2 (en) 2012-06-21 2019-08-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
DK3157951T3 (da) 2014-06-17 2020-08-17 Academia Sinica Humaniserede anti-ige-antistoffer, der tværbinder cd23 på b-lymfocytter, men ikke sensibiliserer mastceller
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR20200113228A (ko) * 2018-01-22 2020-10-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항-4-1bb 항체, 이의 항원-결합 단편 및 이의 의학적 용도

Also Published As

Publication number Publication date
JP7128191B2 (ja) 2022-08-30
AU2018205484B2 (en) 2024-11-21
US20230090487A1 (en) 2023-03-23
US20190322766A1 (en) 2019-10-24
JP2022172170A (ja) 2022-11-15
CA3049967A1 (en) 2018-07-12
JP7461420B2 (ja) 2024-04-03
EP3565587A1 (en) 2019-11-13
JP2020505334A (ja) 2020-02-20
AU2018205484A1 (en) 2019-08-01
EP3565587A4 (en) 2020-12-16
US11518818B2 (en) 2022-12-06
WO2018129248A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
US9849165B2 (en) Oligomer-specific amyloid beta epitope and antibodies
AU2021201759A1 (en) Anti-complement C1s antibodies and uses thereof
US10155820B2 (en) Anti-endoglin antibodies and uses thereof
US9926375B2 (en) Anti-endoglin antibodies and uses thereof
US20220273779A1 (en) Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
CN106164675B (zh) 检测人类骨膜蛋白的新型测定
CN104039832B (zh) 抗磷酰胆碱的新抗体
BR112021006123A2 (pt) anticorpos anti-sinucleína
JP2025093954A (ja) ヒト化抗－ｃ５ａ抗体
CN103906532B (zh) 结合磷酰胆碱（pc）和/或pc结合物的抗体
ES2994127T3 (en) Anti-pd-1 antibodies
US20230090487A1 (en) Therapeutic Anti-IgE Antibodies and Methods and Compositions Thereof
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
US10196458B2 (en) Anti-immunoglobulin E antibodies and methods of using thereof
JP2022172170A5 (cg-RX-API-DMAC7.html)
CN119546631A (zh) 用于治疗支气管扩张的抗PcrV和Psl双特异性抗体
US20240026035A1 (en) Human ige monoclonal antibodies to antibodies to alpha-gal (galactose-a-1,3-galactose) and uses therefor
US20230220053A1 (en) ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOF
RU2820628C2 (ru) Белки, связывающие глюкагоновые рецепторы, и способы их применения
Khatri Structural and Immunological Characterization of Inhaled Allergens and Their Complexes With Antibodies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802